PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

FREE AND TOTAL PSA CONCENTRATIONS, IN SERUM RANGING 4,0-10,0 NG/ML IN CARCINOMA AND BPH DIAGNOSIS
Article published in Urologia Polska 1998/51/1.

authors

Aleksandra Kochańska-Dziurowicz 1, Katarzyna Kasparkiewicz 1, Michał Mielniczuk 2, Wojciech Szewczyk 3
1 Instytut Medycyny Pracy i Zdrowia Środowiskowego w Sosnowcu
Kierownik: dr hab. n. med. A. Kochańska-Dziurowicz
2 Oddział Urologii Szpitala Górniczego w Bytomiu
Kierownik: dr n. med. L. Teneta
3 I Klinika i Katedra Urologii AM w Katowicach
Kierownik: prof. dr hab. n. med. A. Preisner

keywords

prostate prostate cancer bening prostatic hyperplasia prostatic specific antigen: free and total

summary

Objective. In order to establish value of PSA measurements authors measured
free and total PSA concentrations and PSA density in patients with diagnosis of
prostate carcinoma and benign prostatic hyperplasia confirmed by histopatholo-
gical examination of specimens obtained during prostate electroresection.
Material and methods. Free and total PSA concentrations and prostate volu-
me were measured in 50 patients prior to prostate electroresection. The group of
patients with total serum PSA concentrations ranging 4.0-10.0 ng/ml was selec-
ted. These patients were then divided into two subgroups depending on histo-
pathological diagnosis of biopsy specimens: those with prostate carcinoma and
those with benign prostatic hyperplasia. Free PSA to total PSA concentration ra-
tio and PSA density were calculated. Results were compared with histo-
pathological findings.
Results. A statistically significant difference between PSA densities in two
subgroups was found. Participation of patients with prostate carcinoma in
Particular ranges of PSA concentrations was found to be similar to these presented
by European patients but it was different from results obtained in papers estimated
patients with North America (USA) population. No patients with benign prostatic
hyperplasia were found in range of free PSA to total PSA ratio below 5%.
Probability cases of prostate carcinomas were low in range above 20%.
Conclusions: Free PSA and PSA density measurements extend usefulness of
this marker in early detection of prostate cancer in PSA concentrations ranging
4.0-10.0 ng/ml. They also provide ground for waving prostate biopsy in some
uncertain cases.

references

  1. [1] Becker, Ch., Lilja, H.: Individual Prostate-specific antigen (PSA) forms as pro-
  2. state tumor markers. Clin. Chem. Acta, 1997, 257, 117-132.
  3. [2] Catalona, W. J., Richie, J. P., deKernion, J. B., Ahmann, F. R., Ratliff, T.
  4. I., Dalkin, B. I., Kavoussi, L. R., MacFarlane, M. T., Southwick, P. C:
  5. Comparison of prostate specific antigen concentration versus prostate specific
  6. antigen density in the early detection of prostate cancer: receiver operating cha-
  7. racteristic curues. J. Urol. 1994, 152, 2031-2036.
  8. [3] Christensson, A., Bjork, T., Nilsson, O., Dahlen, U., Matikainen, M., Coc-
  9. klett, A. T., Abrahamsson, P., Lilja, H.: Serum prostate specific antigen com-
  10. plexed to ?l-antichymotrypsin as an indicator of prostate cancer. J. Urol. 1993,
  11. 150, 100-105.
  12. [4] Hanley, J. A., McNeil, B. J.: The meaning and use of the area under a rece-
  13. iver operating characteristic (ROC) curve. Radiology 1982, 143, 29-36
  14. [5] Higashihara, E., Nutahara, K., Kojima, M., Okegawa, T., Miura, I.
  15. i wsp.: Significance of serum free prostate specific antigen in the screening of
  16. prostate cancer. J. Urol. 1996, 156, 1964-1968.
  17. [6] Irani, J., Millet, C, Levillain, P., Dore, B., Begon, M., Aubert, J.: Serum-
  18. to-urinary prostate specific antigen ratio: its impact in distingnishing prostate
  19. cancer when serum prostate specific antigen level is 4 to 10 ng/ml. J. Urol.
  20. 1997, 157 (1), 1858.
  21. [7] Kulpa, J.: Swoisty antygen sterczowy (PSA)-wybrane aspekty użyteczności w dia-
  22. gnostyce biochemicznej chorych na raka stercza. Nowotwory z. II, 1996, 293-322.
  23. [8] Kulpa, J., Wójcik, E., Soboń, M., Dobrowolski, Z.: Wolny i związany z alfa-
  24. 1-antychymotrypsyn PSA ? nowy parametr w diagnostyce różnicowej raka
  25. i gruczolaka stercza. Diag. Lab. 1996, 32, 91-99.
  26. [9] Lilja, H.: Significance of different molecular forms of serum PSA; the free, non-
  27. complexed form of PSA versus that complexed to alpha-1-antichymotrypsin. Urol.
  28. Clin. North Am. 1993, 20, 681.
  29. [10] Lilja, H., Christensson, A., Dahlen, U., Matikainen, M., Nilsson, O., Pet-
  30. tersson, K., Lovgren, T.: Prostate specific antigen in serum occurs predomi-
  31. nantly in complex with al-antichymotrypsin. Clin. Chem. 1991, 1618-1625.
  32. [11] Luderer, A.A., Chen, Y.T., Soriano, T.R, Kramp, W.J., Carlson, G., Cuny
  33. C, Shaarp, T., Smith, W., Petteway, J., Brawer, M.K., Thiel, R.: Measu-
  34. rement of the proportion of free to total Prostate-specific antigen improves dia-
  35. gnostic performance of Prostate-specific antigen in the gray zone of total Pro-
  36. state-specific antigen. Urology 1995, 45, 187-195.
  37. [12] Prestigiacomo, A.F., Stamey, T.A.: Can free and total prostate specific anti-
  38. gen and prostatic volume distiguish between men with negatwe and positive
  39. systematic ultrasound guided prostate biopsies. J. Urol. 1997, 157, 189-194.
  40. [13] Stamey, T.A., Chen, Z., Prestigiacomo, A.: Serum prostate specific antigen
  41. binding ?l-antichymotrypsin: influence of cancer volume, location and thera-
  42. peutic selection of resistant clones. J. Urol. 1994, 152, 1510-1514.
  43. [14] Van Cangh, P.J., De Nayer, R, Sauvage, R, Tombal, B., Elsen, M., Lorge,
  44. R, Opsomer, R., Wese, F.X.: Free to total Prostate-specific antigen (PSA) ratio
  45. is superior to total-PSA in differentiating benign prostate hypertrophy from
  46. prostate cancer. Prost. Supl. 1996, 7, 30-34.
  47. [15] Wolff, J.W., Scholz, A., Boeckmann, W., Jakse, G.: Differentiation of benign
  48. prostatic hyperplasia and prostate cancer employing Prostatic-specific antigen
  49. density. Eur. Urol. 1994, 25, 295-298.